Evaluation of the QuantiFERON-TB Test.

QIAGEN Gaithersburg, Inc15 enrolled

Overview

To compare the results of the investigational test to the currently approved QuantiFERON-TB Gold In-Tube test.

To compare the sensitivity of the CST001 assay to the QuantiFERON-TB Gold assay in patients with bacteriologically confirmed and untreated TB disease.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Tuberculosis

Interventions

CST001DEVICE

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical symptoms consistent with a high probability of having TB disease * Receiving, or are likely to receive, therapy for active TB * Confirmed tuberculosis by either AFB smear and culture testing, or Nucleic Acid Amplification methods and culture testing. * Between 18 and 70 years of age. Exclusion Criteria: * Taken therapy for active TB or latent TB for more than 14 days * Culture confirmation of M. tuberculosis not obtained

Locations (1)

University of Washington

Seattle, Washington, United States

Outcomes

Primary Outcomes

Number of Participants With Clinical Signs/Symptoms Indicating TB With a Positive CST001 Assay Result as an Indication of Clinical Sensitivity

Subjects who have clinical signs/symptoms indicating TB and who are receiving or have to start the treatment for active TB were tested. Subjects who were presenting with symptoms suggestive of TB disease and who have a positive acid-fast bacillus (AFB) smear or have Mycobacterium tuberculosis (MTB) in a specimen detected by nucleic acid amplification (NAA) or MTB complex Polymerase Chain Reaction (PCR), and who have received treatment for no more than 14 days upon enrollment.

Time frame: At time of enrollment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.